LAB282 Expert in Residence
Head of Academic Partnerships at Evotec.

Since November 2016, Thomas has been responsible for strategic academic partnerships at Evotec. From November 2013, Thomas has been EVP of Immunology and Inflammation, heading a portfolio of drug discovery projects in the areas of inflammation and immuno-oncology at Evotec. During this time, Thomas’ focus has been on building high-value, performance based drug discovery alliances with academia and pharma.

From 2007 to 2013, Thomas was Sourcing Director at the Biopharmaceuticals Research Unit of Novo Nordisk, where he identified and evaluated multiple partnering opportunities related to compounds, targets and technologies for several therapeutic areas.

Prior to joining Novo Nordisk, Thomas was co-founder and Chief Scientific Officer at TeGenero, a German biotech company developing therapeutic monoclonal antibodies.

As LAB282 EIR, Thomas works closely with academics and with Oxford University Innovation to source and manage funded projects.


LAB282 Scientific Expert
VP of Academic Partnerships at Evotec.

Mark is responsible for the identification and execution of drug discovery programs under Evotec´s academic bridge umbrella. Mark works closely with investigators across the university to identify interesting, promising opportunities and help shape these programs. Mark brings a wealth of expertise in drug discovery into this role with over 15 years in the drug discovery arena across many therapeutic areas, target classes also in the context of new spin outs through to large pharma. Extending the success of the academic bridge model to other leading institutes across Europe is also one of Mark´s areas of responsibilities.

Prior to his current role Mark was VP In vitro pharmacology responsible for drug discovery activities within the context of Evotec´s execute and innovate business segments. During this time Mark saw the development of several programs now in Phase 1 and Phase 2 clinical testing and was also pivotal in introducing key technologies into the company.